Healthcare >> Analyst Interviews >> October 26, 2004
TWST: Would you begin with a quick overview of your coverage in biotech? ELEMER PIROS is a senior biotechnology analyst at Rodman & Renshaw, Inc.
Previously, Dr. Piros was a buyside biotechnology analyst at Spear,
Leeds & Kellogg, now a wholly owned subsidiary of Goldman Sachs. From
1990 to 2000, Dr. Piros conducted academic research in the field of
neuroscience, focusing on understanding the molecular mechanism of
communication in the nervous system. He has published his findings in
peer-reviewed scientific journals. Dr. Piros earned degrees in
mathematics and in biology and a PhD in neuroscience at the University
of California at Los Angeles. He then completed post-doctoral training
at Cornell University Medical College in New York. Currently, Dr. Piros'
research universe includes emerging biotechnology companies that develop
products addressing the nervous system and cancer. Profile
Mr. Piros: We currently have 14 names under coverage. These would fall
into the $100 million to $500 million market